Company intelligence / Profile preview
DarwinCell
San Diego, California, United Statesdarwincell.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DarwinCell is a clinical-stage biotechnology company dedicated to developing next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer. The company utilizes a proprietary platform designed to engineer T-cells with enhanced persistence and anti-tumor efficacy, specifically addressing the challenges of T-cell exhaustion. DarwinCell's pipeline includes candidates targeting both hematological malignancies and difficult-to-treat solid tumors, such as liver and prostate cancer. By optimizing the selection and manufacturing of therapeutic cells, the company aims to provide more durable clinical outcomes for patients with advanced malignancies.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCell therapyLentiviral vector
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on DarwinCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DarwinCell.